Drug Discovery

#Drug discovery #Drug targets #Enhanced Genomics #Genomics #Multi-omics

Part 2: A day exploring Cambridge’s life science scene

DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with several local companies and attended events. The first of this series was a conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. Here, DDW summarises what was learnt about… Read More

#Exclusive Content

#Cancer research #Drug discovery #Personalised medicine #Perspective Therapeutics #Radiopharmaceuticals

New podcast: Redefining oncology with radiopharmaceuticals

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Thijs Spoor, CEO… Read More

#News

London skyline
#Drug discovery #Events #Turning Science into Business Symposium

DDW Symposium attracts key drug discovery speakers

The DDW Turning Science into Business Symposium boasts a stellar line up of speakers sharing their insight on the opportunity and expertise within the drug discovery and development market. Later this year DDW will be holding its Turning Science into Business Symposium at the Francis Crick Institute in London. The… Read More

#Exclusive Content

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

New DDW Highlights podcast: 21 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s news highlights reflect the incredible levels of innovation and investment, but also the… Read More

#News

#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy

This week in drug discovery (14-18 July) 

News round-up for 14-18 July by DDW Senior Digital Content Editor Diana Turner. This week’s news highlights reflect the incredible levels of innovation and investment, but also the hurdles to overcome, in developing gene therapies – breakthrough treatments in many genetic diseases that can bring their own unique… Read More

#News

#Cancer research #Cell profiling #Drug development #Financing #Next generation sequencing #One Biosciences

€15 million to advance clinical single cell profiling

One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities. The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences’ total funding… Read More

#Business & Investment #News

FDA headquarters
#Cancer research #Drug discovery #FDA #Fujifilm #Regulatory

FUJIFILM’s biliary tract cancer drug granted FDA orphan status

FUJIFILM Pharmaceuticals’ FF-10832—an investigational liposomal formulation of gemcitabine—has granted orphan drug designation for the treatment of biliary tract cancer (BTC) by the US Food and Drug Administration (FDA). FF-10832 is currently being evaluated in Phase IIa studies as monotherapy or in combination with pembrolizumab for the treatment of solid tumours… Read More

#Cancer Research #News

#Drug discovery #Europe #European Commission #European Union

New DDW Highlights podcast: 14 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week our news highlights focus on the drug discovery in the European Union, including… Read More

#News

#Denmark #Drug development #Funding #Obesity #Pila Pharma #Type 2 diabetes #Weight loss

Biotech raises capital for new oral obesity treatment

Biotech company Pila Pharma has raised 20 million Swedish kronor ($2.08 million) in an almost fully covered capital raise, which includes a stock option for future use. Pila Pharma was founded by Danish researcher Dorte Gram, a former researcher at Novo Nordisk and was the first researcher to screen… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Biopharma #Biotechnology #Drug discovery #Genetics / genomics

DDW Summer edition – out now!

The DDW Summer issue is available to read now. It features in-depth articles on the technologies and advancements driving genomics drug discovery, how supercomputing can drive neuroscience discoveries, and everything you need to know about spatial biology.  Other features include:   A market report on… Read More

#Editor's Choice #News

#Drug discovery #Europe #European Commission #European Union

This week in drug discovery (7-11 July) 

News round-up for 7-11 July by DDW Senior Digital Content Editor Diana Turner. This week our news highlights focus on the drug discovery in the European Union, including some new regulatory approvals from the European Commission, advancements from Netherlands-based argenx, a new PhD programme in Estonia, and Switzerland’s… Read More

#News

Automated liquid handling
#Automation / robotics #Cellular assays #Collaboration #Drug discovery #Semarion #SPT Labtech

SPT Labtech and Semarion partner on automated cell-based discovery

SPT Labtech and Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory, have announced a strategic collaboration.   The partnership will integrate SPT Labtech’s firefly liquid handling platform with Semarion’s SemaCyte microcarrier technology to develop an automated workflow to simplify and accelerate key stages of adherent… Read More

#Business & Investment #News

#Drug discovery #Flow Cytometry #High throughput screening #Sartorius

Sartorius introduces the iQue 5 high throughput screening platform

The life science group Sartorius has launched the new iQue 5 High-Throughput Screening (HTS) Cytometer. The iQue 5 expands experimental range with up to 27 channels (25 colour options) and flexible workflows in 96- and 384-well formats. “For scientists driving the next breakthrough in… Read More

#News

Human gastrointestinal tract
#Assays #Drug discovery #Guide #In vivo #Obesity #Weight loss

Guide: Accelerate your weight loss drug discovery

A new Guide is now available from Eurofins Discovery entitled ‘Drug Discovery for Anti-Obesity‘. Explore obesity case studies profiling semaglutide, tirzepatide, and retatrutide using Eurofins Discovery’s weight-loss solutions. Advance your obesity program with on/off-target panels, translational assays, in vivo models, and MOA-reflective tools. Partner with expert scientists and program… Read More

#News

Drug Discovery for Anti-Obesity
#Assays #Drug discovery #In vivo #Obesity #Weight loss

Accelerate your weight loss drug discovery

Explore obesity case studies profiling semaglutide, tirzepatide, and retatrutide using Eurofins Discovery’s weight-loss solutions. Advance your obesity program with on/off-target panels, translational assays, in vivo models, and MOA-reflective tools. Partner with expert scientists and program managers for strategic guidance and scientific leadership on your integrated drug discovery programs targeting weight-loss… Read More

#Resources

Antibody
#Antibodies #argenx #Biology #Biotechnology #Drug development #Drug discovery #Muscles

argenx advances ARGX-119 in congenital myasthenic syndromes 

argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS). The decision follows the analysis of topline data from the Phase Ib study, in which ARGX-119 demonstrated a favourable safety and tolerability profile. “The… Read More

#News